Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.62B
Market cap12.62B
Price-Earnings ratio
-36.16
Price-Earnings ratio-36.16
Dividend yield
Dividend yield
Average volume
2.07M
Average volume2.07M
High today
$77.40
High today$77.40
Low today
$75.87
Low today$75.87
Open price
$76.45
Open price$76.45
Volume
226.15K
Volume226.15K
52 Week high
$86.74
52 Week high$86.74
52 Week low
$31.66
52 Week low$31.66

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $76.39, giving the company a market capitalization of 12.62B. It carries a P/E multiple of -36.16.

As of 2026-05-08, Ionis Pharmaceuticals(IONS) stock has fluctuated between $75.87 and $77.40. The current price stands at $76.39, placing the stock +0.7% above today's low and -1.3% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 226.15K, against a daily average of 2.07M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $31.66 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $31.66 at its lowest and $86.74 at its peak.

IONS News

Simply Wall St 2d
Should FDA Priority Review Of Bepirovirsen And Higher 2026 Guidance Require Action From Ionis Investors?

In late April 2026, partner GSK announced that the FDA accepted for Priority Review the New Drug Application for bepirovirsen, an antisense therapy for chronic...

Should FDA Priority Review Of Bepirovirsen And Higher 2026 Guidance Require Action From Ionis Investors?
Simply Wall St 4d
A Look At Ionis Pharmaceuticals Valuation After FDA Priority Review Wins And Upgraded Revenue Guidance

Ionis Pharmaceuticals (IONS) has been in focus after a busy stretch that included US FDA Priority Review and Breakthrough Therapy designations for partner drug...

A Look At Ionis Pharmaceuticals Valuation After FDA Priority Review Wins And Upgraded Revenue Guidance

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.